---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-25-000033"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:28:02.703317+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Halozyme Q2 revenue $326M (+41% YoY); raises FY25 guidance, files patent suit vs Merck

## Summary
- Q2 total revenue $325.7M (+41% YoY); royalty revenue $205.6M (+65% YoY).
- GAAP diluted EPS $1.33 (+85% YoY); Non-GAAP diluted EPS $1.54 (+69% YoY).
- Raises 2025 total revenue guidance to $1.275-1.355B (26-33% YoY) and Non-GAAP EPS to $6.00-6.40.
- Completed $303M share repurchases in Q2; initiated third $250M tranche under $750M program.
- Filed patent infringement lawsuit against Merck alleging unauthorized use of MDASE technology for SC Keytruda.

## SEC filing metadata
- accession: 0001159036-25-000033
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000033/0001159036-25-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000033/halo-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-25-000033
- JSON: https://secwatch.observer/filing/0001159036-25-000033.json
- Plain text: https://secwatch.observer/filing/0001159036-25-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.